Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan

Hoshi Shu-ling; Seposo Xerxes; Shono Aiko; Okubo Ichiro; Kondo Masahide

首页> 外文期刊>Vaccine >Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan

【24h】

Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan

机译：重组带状疱疹疫苗（RZV）和水痘疫苗活（VVL）的成本效益（RZV）对疱疹疱疹和在日本65岁及以上的成年人的疱疹后神经痛中

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The approval of the extended use of 1-dose varicella vaccine (VVL) in adults aged 50 and older against herpes zoster (HZ) in 2016 and the 2-dose recombinant zoster vaccine (RZV) in 2018 raised the need to evaluate the value for money between these two vaccines.

机译：背景：2016年患有50岁及以上疱疹（Hz）的成人延长使用的1剂水痘疫苗（VVL）的批准和2018年的2剂重组带状疗法（RZV）提出了评估的需要这两个疫苗之间的资金值。

著录项

来源
《Vaccine》 |2019年第27期|共10页
作者
Hoshi Shu-ling; Seposo Xerxes; Shono Aiko; Okubo Ichiro; Kondo Masahide;
展开▼
作者单位

Univ Tsukuba Fac Med Dept Hlth Care Policy &

Hlth Econ 1-1-1 Tennoudai Tsukuba Ibaraki 3058577 Japan;

Kyoto Univ Dept Environm Engn Environm Hlth Div Nishikyo Ku Kyoto 6158246 Japan;

Meiji Pharmaceut Univ Fac Pharmaceut Sci Dept Publ Hlth &

Epidemiol 2-522-1 Noshio Tokyo 2048588 Japan;

Yokohama City Inst Publ Hlth Kanazawa Ku 7-1 Tomiokahigashi 2 Chom Yokohama Kanagawa 2360051 Japan;

Univ Tsukuba Fac Med Dept Hlth Care Policy &

Hlth Econ 1-1-1 Tennoudai Tsukuba Ibaraki 3058577 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词
Cost-effectiveness; Economic evaluation; Herpes zoster; Varicella vaccine; Vaccination; Quality-adjusted life year;

机译：成本效益;经济评价;疱疹带;水痘疫苗;疫苗接种;质量调整的终身年;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan [J] . Hoshi Shu-ling, Seposo Xerxes, Shono Aiko, Vaccine . 2019,第27期

机译：重组带状疱疹疫苗（RZV）和水痘疫苗活（VVL）的成本效益（RZV）对疱疹疱疹和在日本65岁及以上的成年人的疱疹后神经痛中
2. Response to publication by Hoshi SL et al.: Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan [J] . Desmond Curran, Tomas Mrkvan Vaccine . 2017,第51期

机译：回应Hoshi Sl等人的出版物：Daricella疫苗对疱疹疱疹疫苗和日本老年人后疱疹后神经痛的成本效果
3. Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65?Years and Older [J] . Makoto Shiragami, Akiko Mizukami, Toshihiko Kaise, Dermatology and Therapy . 2019,第2期

机译：65岁及以上日本成年人佐剂重组带状疱疹疫苗的成本效益
4. Development of a Targeted LC-MRM/MS Assay for the Quantitation of Varicella Zoster Virus Vaccine Proteins [C] . Kristin Geddes, Colleen Price, Jianfang Hu, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：用于定量VariCella带状疱疹病毒疫苗蛋白的目标LC-MRM / MS测定的开发
5. Engineering a live attenuated vaccine: Mutational analysis of varicella-zoster virus (VZV) glycoproteins,gI andgE, in recombinant VZV strains. [D] . Mallory, Suzanne. 1997

机译：设计减毒活疫苗：重组VZV株中水痘带状疱疹病毒（VZV）糖蛋白，gI和gE的突变分析。
6. Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older [O] . Makoto Shiragami, Akiko Mizukami, Toshihiko Kaise, 2019

机译：65岁及以上日本成年人佐剂重组带状疱疹疫苗的成本效益
7. Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older [O] . Makoto Shiragami, Akiko Mizukami, Toshihiko Kaise, 2019

机译：日本成年人的佐剂重组带状疫苗的成本效益为65岁及以上

Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan

摘要

著录项

相似文献

相关主题

期刊订阅